Adverse Event reporting information can be found in footer

Request a Meeting


GnRH antagonist to prevent premature LH surge in women undergoing controlled ovarian stimulation1


Fyremadel® is indicated for the prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART)

Ready to use in a pre-filled syringe for subcutaneous administration


Here you can access our past webinar and lecture series on demand

  1. Fyremadel Summary of Product Characteristics. Fyremadel 0.25 mg/0.5 ml solution for injection in pre-filled syringe. Available: (last accessed July 2023).

Job Code: UK-FYR-2300001 - Date of preparation: August 2023


Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.